...
首页> 外文期刊>Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract >The Primary Result of Prospective Randomized Multicenter Trial of New Spray-Type Bio-absorbable Adhesion Barrier System (TCD-11091) Against Postoperative Adhesion Formation
【24h】

The Primary Result of Prospective Randomized Multicenter Trial of New Spray-Type Bio-absorbable Adhesion Barrier System (TCD-11091) Against Postoperative Adhesion Formation

机译:新型喷雾型生物可吸收粘附屏障系统(TCD-11091)对术后粘附形成的前瞻随机多中心试验的主要结果

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background Postoperative adhesions are the major cause of postoperative complications including intestinal obstruction, infertility, and chronic pelvic pain. In order to reduce postoperative adhesions, Terumo Corporation (Tokyo, Japan) has developed an adhesion barrier system (TCD-11091) which is easy to use at the treatment site in various surgical procedures including laparoscopic surgeries. We conducted a prospective randomized single-blind study in patients who underwent laparotomy with ileostomy. Methods and Results One hundred twenty-six patients were randomly assigned to TCD-11091 group ( n ?=?62) or non-treatment group ( n ?=?62). Patient backgrounds were similar between the groups. At the time of ileostomy closure (the second-look surgery), the observation was performed on 55 in the TCD-11091 group and 43 in the control group. The incidence of adhesions observed at the second-look surgery was significantly lower in the TCD-11091 group (52.7 versus 90.7%; p ? p ? p ? p ?=?0.225). Conclusions Use of TCD-11091 was safe and associated with significantly lower incidence of adhesion and severity of adhesions compared with non-treatment procedure.
机译:摘要背景术后粘连是术后并发症,包括肠梗阻,不孕症和慢性骨盆疼痛的主要原因。为了减少术后粘连,Terumo Corporation(东京,日本)开发了一种粘附阻挡系统(TCD-11091),其在各种外科手术中易于使用,包括腹腔镜手术。我们对接受剖腹术的患者进行了一项前瞻性随机单盲研究。方法和结果一百二十六名患者被随机分配给TCD-11091组(N?=α62)或非治疗组(n?=?62)。患者背景是相似的。在对照闭合(第二外科)时,在TCD-11091组和对照组中的43中进行了55次进行观察。 TCD-11091组在第二外科手术中观察到的粘连发生率显着较低(52.7与90.7%;p≤p≤p≤p≤0.225)。结论使用TCD-11091是安全的,与无治疗程序相比,粘附性和粘连性严重程度明显降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号